Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...

Scientists have engineered CAR-T cells with on/off switches activated by existing drugs, enhancing safety in cancer therapy.

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety and ...

The first patient has been successfully imaged, marking a milestone in the development of this copper-based ...

Global Cancer Antibody Drug Conjugates Market: 2020 - 2030 Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 ...

Prostate cancer is one of the most common forms of cancer in men – affecting over 55,000 a year in the UK, with 150 new cases ...

Antibodies show promise as candidates for therapeutics as well as tools for advancing mechanistic studies of the HER family receptors.

Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration ...

BriaCell Therapeutics could access a $1-$5 billion market upon approval despite a sub-$30 million cap. See more on BRIA stock ...

ADRX-0405 is a novel antibody-drug conjugate targeting STEAP1, and a phase 1a/b study will investigate the agent for the ...